White Pine Capital’s Viridian Therapeutics VRDN Stock Holding History

White Pine Capital’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-106	Closed	-$51K	–	217
2015 Q1	$51K	Buy	+106	New	+$61.3K	0.02%	209

Other funds holding VRDN

PCM

Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

SGH

Schonfeld Group Holdings Jericho, New York $158M AUM 12.17% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

FNYS

First New York Securities New York $53.7M AUM 57.01% 1-Year Est. Return

AIG

American International Group New York $609M AUM 23.67% 1-Year Est. Return

White Pine Capital's VRDN Position: Q2 2015 in Review

White Pine Capital sold out of Viridian Therapeutics (VRDN) in Q2 2015, closing a stake of 106 shares — an estimated $51K sold.

White Pine Capital first reported a position in VRDN in Q1 2015 and held it in 1 quarter. The position peaked at $51K in Q1 2015. 9 funds tracked by Wall St. Rank hold VRDN as of Q2 2015.

White Pine Capital reported no remaining Viridian Therapeutics position as of Q2 2015 after selling out during the quarter.
White Pine Capital sold 106 Viridian Therapeutics shares in Q2 2015, an estimated $51K.
White Pine Capital first reported a position in Viridian Therapeutics in Q1 2015 and held it in 1 quarter.
White Pine Capital's Viridian Therapeutics position peaked at $51K in Q1 2015.
9 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2015.

Based on White Pine Capital's 13F filing for Q2 2015, filed 13 Aug 2015.